Gene-Guided chemo cocktail aims to tame tough pancreatic cancer

NCT ID NCT05929885

Recruiting now Disease control Sponsor: National Cancer Centre, Singapore Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a three-drug chemotherapy regimen given at lower, continuous doses for people with metastatic pancreatic cancer. The drugs—capecitabine, oxaliplatin, and irinotecan—are dosed based on a patient's genetic profile to reduce side effects. The goal is to see if this approach shrinks tumors or keeps them stable for at least six months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: capecitabine, oxaliplatin, irinotecan
What this could lead to: If successful, this could offer a more tolerable chemotherapy option for people with advanced pancreatic cancer, potentially improving response rates.
What could go wrong: This is a small, early-phase trial (50 people) at a single center, so results may not apply broadly. The chemo still carries risks like fatigue, nausea, and low blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PANCREATIC CANCER

Contacts and locations

Locations

National Cancer Centre, Singapore
RECRUITING

Singapore, 168583, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.